Information For the User Glimepiride (2mg) + Metformin (500mg) SR + Voglibose (0.2mg) Bilayered Smart Tablet

Vogliviga GM2/0.2 Tablet

Composition (per tablet):

Glimepiride (2mg) + Metformin Hydrochloride SR (500mg) + Voglibose (0.2mg)

Description:

Vogliviga GM2/0.2 Tablet is a triple-combination antidiabetic medication designed for effective management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates insulin secretion from pancreatic beta cells. Metformin SR improves insulin sensitivity and decreases hepatic glucose production. Voglibose delays carbohydrate absorption in the intestines, reducing postprandial blood sugar spikes.

Indications:

- Type 2 Diabetes Mellitus requiring combination therapy
- Patients inadequately controlled on dual therapy
- Control of fasting and postprandial hyperglycemia

Mechanism of Action:

Glimepiride increases endogenous insulin secretion. Metformin decreases hepatic gluconeogenesis and enhances peripheral glucose uptake. Voglibose inhibits alpha-glucosidase enzymes, slowing carbohydrate digestion and absorption, thus minimizing post-meal hyperglycemia.

Dosage and Administration:

One tablet to be taken once or twice daily with meals or as prescribed by the physician. Dosage adjustments should be based on blood glucose monitoring and clinical response.

Contraindications:

- Hypersensitivity to any components
- Diabetic ketoacidosis or severe metabolic acidosis
- Severe renal or hepatic impairment
- Type 1 diabetes mellitus

Precautions:

Monitor blood glucose and renal function regularly. Use caution in elderly patients and those with comorbid conditions. Educate patients about symptoms of hypoglycemia.

Side Effects:

- Hypoglycemia
- Gastrointestinal discomfort such as nausea, vomiting, diarrhea
- Allergic skin reactions (rash, itching)
- Rare cases of lactic acidosis

Storage:

Store below 30°C in a dry place away from direct sunlight. Keep out of reach of children.

Manufactured in India for:

